Stage IIIA-N2 NSCLC: A review of its treatment approaches and future developments

Meerbeeck, Jan P. van; Surmont, Veerle

doi:10.1016/j.lungcan.2009.02.007

Cited by 37 publications

(19 citation statements)

References 96 publications

(113 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[7][8][9] The third edition of the American College of Chest Physicians evidence-based clinical practice guidelines recommend that treatment plan for patients with discrete N2 involvement by NSCLC identified preoperatively (IIIA) should be made with the input from a multidisciplinary team. [9] Ratto et al showed good long-term survival and excellent local disease control in their study.…”

Section: Discussionmentioning

confidence: 99%

Prognostic factors in resectable pathological N2 disease of non-small cell lung cancer

Hsieh

Liu

et al. 2015

Biomed J

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Prognostic factors in resectable pathological N2 disease of non-small cell lung cancer

Hsieh

Liu

et al. 2015

Biomed J

View full text Add to dashboard Cite

“…If FDG was not found to have accumulated in the lymph nodes at PET/CT scan, we should diagnose as cN0 and make the decision on therapeutic principle. If incidental lymph node metastases of N1 or N2 station are found on final pathology examination of the resected specimen, we should treat by using surgical resection followed by adjuvant chemotherapy (17).…”

Section: Discussionmentioning

confidence: 99%

Diagnosis of the presence of lymph node metastasis and decision of operative indication using fluorodeoxyglucose-positron emission tomography and computed tomography in patients with primary lung cancer

et al. 2010

View full text Add to dashboard Cite

: Objectives : We evaluate whether integrated fluorodeoxyglucose-positron emission tomography and computed tomography (FDG-PET/CT) scan can diagnose the presence of lymph node metastasis more accurately than computed tomography (CT) scan alone. Methods : Forty-two patients with lung cancer preoperatively underwent integrated PET/CT scan using FDG and CT scan and underwent pulmonary resection and lymph node dissection. We judged cases as lymph node metastasis if the lymph node visually accumulated FDG at PET/CT scan and measured 1 cm or greater in the short axis at CT scan. We retrospectively analyzed whether our judgments in each modality were consistent with the pathological diagnosis. Results : Two-hundred and seventeen stations of lymph node were dissected and 21 stations (9.7% %) were histologically diagnosed as positive metastasis. Thirty-two stations of lymph node visually accumulated FDG at PET/CT scan and 17 stations measured 1 cm or greater in the short axis at CT scan. Concerning the diagnosis of lymph node metastasis, PET/CT scan showed significantly higher sensitivity than CT scan (81% % vs. 48% %, p=0.024). The false-positive rate was significantly high in PET-positive lymph nodes measuring less than 1 cm in diameter. There were 4 falsenegative lymph nodes with both scans. All of these were less than 7 mm in diameter and had a low percentage of metastatic foci in the lymph node. Concerning the diagnosis of N staging, there was no significant difference between PET/CT scan and CT scan (83% vs. 69% %, p=0.124). However, the identification of N2 disease at PET/CT scan was significantly more accurate than that at CT scan (100% % vs. 38% %, p=0.031). Conclusions : PET/CT is superior to CT scan in lymph node staging. However, because the false-positive rate is high in PET-positive lymph nodes measuring less than 1 cm in diameter, we think that clinical background should be considered and other modalities or histological examinations should be undertaken if necessary. J. Med. Invest. 57 : 305-313, August, 2010

show abstract

“…Non-small cell lung cancer (NSCLC) is the major form present, which is initiated in the non-small cells of the lung and readily develops into malignant cancer that spreads throughout the body (3,4). Previous studies have demonstrated that NSCLC has the highest incidence rate among all cancer types worldwide (5,6). It is the most common type of lung cancer accounting for >80% of all lung cancer cases and includes squamous cell carcinoma, large cell carcinoma and adenocarcinoma (7)(8)(9).…”

Section: Introductionmentioning

confidence: 99%

Contrast-enhanced ultrasound with a novel nanoparticle contrast agent for clinical diagnosis in patients with non-small cell lung cancer

Han

Jing

2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Non-small cell lung cancer (NSCLC) initiates in the non-small cells of the lung and is one of the most common types of human cancer. It is known for its rapid growth, easy migration, invasion and reoccurrence, and has the highest incidence rate of all types of cancer. Early detection of NSCLC is difficult to achieve and this is the primary reason for low survival rates in NSCLC. Contrast-enhanced ultrasound is the most common application for evaluating patients diagnosed with NSCLC. In the present study, a contrast-enhanced ultrasound combined with nanoparticles was performed with the aim of identifying patients with NSCLC at an early stage. The present study evaluated the effectiveness of administering a nanoparticle contrast agent through respiration in combination with enhanced ultrasound at improving image quality compared with traditional ultrasound. This maybe a novel method of detecting early-stage tumors in patients. There are numerous benefits to conducting diagnoses of NSCLC using contrast-enhanced ultrasound. It is a non-invasive imaging modality, induces little pain, has a low cost, an extensive range and produces high-resolution images. This means that it is safer and more beneficial to use in patients with NSCLC than conventional imaging examinations, including X-ray and bronchoscopy. Furthermore, the nanoscale microbubble contrast agent containing liposome-encapsulated epidermal growth factor receptor was inhaled by nebulization, which may lead to an enhanced ultrasound image. The sensitivity of contrast-enhanced ultrasound was investigated in mice with early stage NSCLC. The results indicated that ultrasound administrated with nanoscale microbubble enhanced sensitivity and improved image quality compared with simple ultrasound. Furthermore, enhanced ultrasound resulted in a reliable and sensitive assessment of tumor mass in early-stage tumors. Altogether, contrast-enhanced ultrasound facilitated the efficient detection of NSCLC in patients in situ at an early stage. This protocol improved the understanding of the pathophysiology of NSCLC and may be applied in the detection of early-stage tumors in patients suspected of having cancer.

show abstract

Stage IIIA-N2 NSCLC: A review of its treatment approaches and future developments

Cited by 37 publications

References 96 publications

Prognostic factors in resectable pathological N2 disease of non-small cell lung cancer

Prognostic factors in resectable pathological N2 disease of non-small cell lung cancer

Diagnosis of the presence of lymph node metastasis and decision of operative indication using fluorodeoxyglucose-positron emission tomography and computed tomography in patients with primary lung cancer

Contrast-enhanced ultrasound with a novel nanoparticle contrast agent for clinical diagnosis in patients with non-small cell lung cancer

Contact Info

Product

Resources

About